

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Partridge, Edward E.

eRA COMMONS USER NAME (credential, e.g., agency login): eepartridge

POSITION TITLE: Director, UAB Comprehensive Cancer Center; Professor, Department of Ob/Gyn

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Alabama, Tuscaloosa, AL	B.S.	09/65-06/69	Chemistry
University of Alabama at Birmingham	M.D.	09/69-06/73	Medicine
University of Alabama at Birmingham	Residency	07/73-06/77	Ob/Gyn
University of Alabama at Birmingham	Fellowship	07/77-06/79	Gyn Oncology

A. Personal Statement

I am particularly well qualified to serve as PI and Director of this Cancer Center Support Grant for the University of Alabama at Birmingham Comprehensive Cancer Center. I have been the PI of the CCSG since 2007. I have experience in clinical, translational, cancer prevention and control, community based participatory and outcomes research and in training. I have served as institutional PI for the former Gynecologic Oncology Group (clinical), PI of both a UAB Ovarian Cancer SPORE and Cervical Cancer SPORE (in collaboration with Johns Hopkins [translational]), PI of the NCI funded ALTs Trial (cancer prevention), PI of the NCI funded Morehouse School of Medicine/Tuskegee University/UAB Comprehensive Cancer Center Partnership (training). I am currently PI of the NCI funded Deep South Network for Cancer Control (CBPR) and PI of the Centers for Medicare and Medicaid Innovation Center funded Patient Care Connect Program evaluating impact of lay navigators on cancer care utilization across the cancer continuum (outcomes). I am a highly qualified scientist with a broad range of experience in many types of research. I also have significant administrative and leadership experience prior to assuming the role of Director. I served as Director of the Division of Gynecologic Oncology, Associate Director for Prevention and Control, and Co-leader of the Cancer Control and Population Sciences Program in the Cancer Center. I have also held leadership in several national cancer organizations. I served as Chairman of the Commission on Cancer of the American College of Surgeons in 1996 and President of the National Board of Directors of the American Cancer Society in 2011. I have also demonstrated excellent leadership in the management of many large complex, multi-investigator, multi-institutional grants as noted above. In addition, I chaired the External Advisory Committee for the Markey Cancer Center of the University of Kentucky providing five years of guidance that led to that institution achieving NCI designation in 2013.

B. Positions and Honors

1976-1979 Instructor, Department of Ob/Gyn, University of Alabama at Birmingham, Birmingham, AL (UAB)
 1979-1986 Clinical Assistant Professor, Department of Ob/Gyn, UAB
 1986-1989 Associate Professor, Department of Ob/Gyn, UAB
 1990-1996 Associate Professor, Department of Ob/Gyn; Scientist; Comprehensive Cancer Center, UAB
 1990-2003 Director, Division of Gynecologic Oncology, Department of Ob/Gyn, UAB
 1991-1996 Associate Professor, Department of Surgery, UAB
 1992-1999 Associate Director for Community Outreach, Comprehensive Cancer Center, UAB
 1993-1999 Director, Cancer Prevention and Control Program, Comprehensive Cancer Center, UAB
 1993-1995 Interim Chairman, Department of Ob/Gyn, UAB
 1995-1996 Medical Director, University of Alabama Health Services Foundation, UAB

1996-1998 Chairman, Commission on Cancer, American College of Surgeons
 1996-2005 Vice Chairman, Department of Ob/Gyn, UAB
 1996-Present Professor, Department of Ob/Gyn
 1996-Present Senior Scientist, Comprehensive Cancer Center, UAB
 1996-Present Professor, Department of Surgery, UAB
 1996-Present Senior Scientist, Center for Aging, UAB
 1999-2007 Margaret Cameron Spain Chair in Obstetrics and Gynecology, UAB
 1999-2008 Associate Director, Prevention and Control Research, Comprehensive Cancer Center, UAB
 1999-2008 Program Leader, Cancer Control and Population Science Program, CCC, UAB
 2000-Present Professor, Gene Therapy Center, UAB
 2002-Present Co-Director, Minority Health & Health Disparities Research Center
 2007-Present Director, Comprehensive Cancer Center, UAB
 2007-Present Evalina B. Spencer Chair in Oncology
 2010-2011 President, American Cancer Society, National Board of Directors

Honors

1969 President, Sigma Alpha Epsilon Social Fraternity University of Alabama, Tuscaloosa
 1969 Alpha Epsilon Delta, Premedical Honorary Clinical
 1970 Summer Clerkship, American Cancer Society
 1992 President's Excellence in Teaching Award, University of Alabama School of Medicine
 1992 Department of Ob/Gyn Outstanding Contribution to the Residency Program Award
 1994 Association of Professors of Gynecology and Obstetrics Excellence in Teaching Award
 1995 Best Doctor in America
 1996 St. Georges Medal for Contributions to Cancer Control, Alabama Division of the ACS
 1996 Chairman, Commission on Cancer of the American College of Surgeons
 1997 Alpha Omega Alpha, National Medical Honor Society
 1997 Good Housekeeping 401 Best Doctors for Women
 1997 Rural Leadership Image Award
 2000 UAB Comprehensive Cancer Center-Distinguished Faculty Award
 2001 Best Doctors in America
 2002 Distinguished Alumnus, UAB
 2002 Ira Meyers Award-Alabama Public Health Association
 2006 Odessa Woolfolk Community Service Award
 2007 ACS Extravaganza Honoree
 2008 Argus Award
 2009 Birmingham Business Journal Health Care Hero Award
 2010 UAB Distinguished Faculty Lecturer
 2011 UA Medical Alumni Association Distinguished Service Award
 2013 American Cancer Society's Humanitarian Award
 2013 White House Champion of Change for Public Health Prevention (Nominee)

C. Contribution to Science

1. My early publications and research interest were focused on gynecologic malignancies with a major emphasis in developing methods for surgical treatment of preinvasive, invasive, and recurrent cervical cancer. These publications set standards for clinical care at the time. For example, the adoption of loop electrical excision of the cervix replacing laser ablation for preinvasive cervical neoplasia, and utilization of radical parametrectomy instead of radiation for post hysterectomy management of unsuspected invasive cervical cancer.
 - a. **Partridge EE**, Beasley WE, Holcomb C, Hatch KD, Shingleton HM, Austin JM Jr. The Swan-Ganz catheter and management of patients undergoing pelvic exenteration. *Obstet Gynecol.* 1979 Feb;53(2):253-5.
 - b. Shingleton HM, Gore H, Soong SJ, Orr JW Jr, Hatch KD, Austin JM Jr, **Partridge EE**. Tumor recurrence and survival in stage IB cancer of the cervix. *Am J Clin Oncol.* 1983 Jun;6(3):265-72.
 - c. Orr JW Jr, Ball GC, Soong SJ, Hatch KD, **Partridge EE**, Austin JM. Surgical treatment of women found to have invasive cervix cancer at the time of total hysterectomy. *Obstet Gynecol.* 1986 Sep;68(3):353-6.

- d. Alvarez RD, Helm CW, Edwards RP, Naumann RW, **Partridge EE**, Shingleton HM, McGee JA, Hall JB, Higgins RV, Malone JM Jr. Prospective randomized trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia. *Gynecol Oncol.* 1994 Feb;52(2):175-9.
2. As the PI of the UAB Clinical Center for the ASCUS Low Grade Triage Study (ALTS), I contributed to the understanding of the role of HPV testing in screening for cervical cancer, leading to the incorporation of HPV testing for management of minimally abnormal pap smears.
 - a. Solomon D, Schiffman M, Tarone R; **ALTS Study group**. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. *J Natl Cancer Inst.* 2001 Feb 21;93(4):293-9.
 - b. Stoler MH, Schiffman M; **ALTS Study Group**. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. *JAMA.* 2001 Mar 21;285(11):1500-5.
 - c. **ASCUS-LSIL Triage Study (ALTS) Group**. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. *Am J Obstet Gynecol.* 200 Jun;188(6):1393-400.
 - d. Guido R, Schiffman M, Solomon D, Burke L; **ASCUS LSIL Triage Study (ALTS) Group**. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. *Am J Obstet Gynecol.* 2003 Jun;188(6):1401-5.
3. I also participated as an investigator in the Prostate Lung Colorectal and Ovarian Cancer (PLCO) screening trial serving as Co-chair of the Ovarian Committee. This trial provided the definitive conclusion that screening for ovarian cancer with CA125 and TVU did not impact mortality and led to clinical guidelines that routine screening for ovarian cancer should not be done. I also provided guidelines to physicians for avoiding surgery for women who were found to have abnormal screens with TVU or CA125.
 - a. Buys SS, **Partridge E**, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK; PLCO Project Team. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. *Am J Obstet Gynecol.* 2005 Nov;193(5):1630-9.
 - b. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS; **PLCO Project Team**. Results from four rounds of ovarian cancer screening in a randomized trial. *Obstet Gynecol.* 2009 Apr;113(4):775-82. PMID: PMC2728067.
 - c. Buys SS, **Partridge E**, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. *JAMA.* 2011 Jun 8;305(22):2295-303.
 - d. **Partridge EE**, Greenlee RT, Riley TL, Commins J, Ragard L, Xu JL, Buys SS, Prorok PC, Fouad MN. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial. *Obstet Gynecol.* 2013 Jan;121(1):25-31. PMID: PMC3711412.
4. Since the mid-nineties I have been engaged in community based participatory research and directed training programs in an attempt to address cancer disparity so prevalent in the southern region of the U.S. served by the UAB Comprehensive Cancer. To that end, we have demonstrated that we can recruit and train lay men and women from underserved communities and effectively increase cancer screening rates in the population. We have extended the utilization of lay navigators across the cancer continuum and are demonstrating that nonprofessional, but trained individuals, can have significant impact in care delivery and reduction in costs.

- a. Lisovicz N, Johnson RE, Higginbotham J, Downey JA, Hardy CM, Fouad MN, Hinton AW, **Partridge EE**. The Deep South Network for cancer control. Building a community infrastructure to reduce cancer health disparities. *Cancer*. 2006 Oct 15;107(8 Suppl):1971-9.
 - b. **Partridge E**, Fouad M. Community-driven approaches for reducing health disparities in cancer. *JAMA*. 2010 Mar 17;303(11):1090-1.
 - c. Fouad M, Wynn T, Martin M, **Partridge E**. Patient navigation pilot project: results from the Community Health Advisors in Action Program (CHAAP). *Ethn Dis*. 2010 Spring;20(2):155-61.
 - d. Scarinci IC, Litton AG, Garcés-Palacio IC, **Partridge EE**, Castle PE. Acceptability and usability of self-collected sampling for HPV testing among African-American women living in the Mississippi Delta. *Womens Health Issues*. 2013 Mar-Apr;23(2):e123-30. PMID: PMC3596478.
5. I have been a leader in developing and executing training programs intended to enhance the ability for minority scientist at both a cancer center and minority serving institutions to compete for extramural funding. Along with my colleagues in the UAB Cancer Center and the Center for Minority Health and Health Disparity Research at UAB training programs have been implemented that have led to the successful development of multiple minority scientists who have developed successful and competitive research programs.
- a. Aikhionbare FO, Mehrabi S, Thompson W, Yao X, Grizzle W, **Partridge E**. mtDNA sequence variants in subtypes of epithelial ovarian cancer stages in relation to ethnic and age difference. *Diagn Pathol*. 2008 Jul 28;3:32. PMID: PMC2494992.
 - b. Matthews R, Azuero A, Asmellash S, Brewster E, **Partridge EE**, Piyathilake CJ. Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race. *Int J Womens Health*. 2011;3:185-92. PMID: PMC3140814.
 - c. Qin Y, Xu J, Aysola K, Begum N, Reddy V, Chai Y, Grizzle WE, **Partridge EE**, Reddy ES, Rao VN. Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins. *J Cell Physiol*. 2011 Dec;226(12):3355-67. PMID: PMC3329759.
 - d. Yu X, Wang F, Liu H, Adams G, Aikhionbare F, Liu D, Cao X, Fan L, Hu G, Chen Y, Frost A, **Partridge E**, Ding X, Yao X. ACAP4 protein cooperates with Grb2 protein to orchestrate epidermal growth factor-stimulated integrin $\beta 1$ recycling in cell migration. *J Biol Chem*. 2011 Dec 23;286(51):43735-47. PMID: PMC3243555.

Complete List of Published Work in MyBibliography:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/edward.partridge.1/bibliography/45280568/public/?sort=date&direction=ascending>

D. Research Support

P30 CA013148 (Partridge) 03/28/97 – 03/31/16
NCI

Comprehensive Cancer Center Core Support Grant

The UAB Comprehensive Cancer Center serves as a major source for effective approaches to cancer prevention, diagnosis, treatment, and survivorship and as a source for delivery of these discoveries, public and professional education, and ultimately as a resource for the local, regional and national community.

Dr. Partridge serves as Director. Role: PI

P50 CA098252 (Wu/Huh) 09/01/15 – 08/31/20

NCI/Subcontract with Johns Hopkins University
SPORE in Cervical Cancer (Career Develop.)

The long-term goal of the Cervical Cancer SPORE is to reduce the incidence, morbidity, and mortality related to cervical cancer within 5 years via rapid translation of specific scientific advances. SPORE projects are translational in nature and address diagnosis, detection, prevention, treatment, and risk assessment for cervical cancer. Role: Co-Investigator

U54 CA153719 (Partridge) 09/07/10 – 08/31/15

NCI

Deep South Network for Cancer Control

Under the direction of the Community Outreach Core, the purpose of this project is to develop, implement, and evaluate a CAP to promote screening for breast, cervical, and colorectal cancer as well as physical

activity and healthy eating among individuals who were unscreened/unreached by previous educational and outreach efforts; and develop, implement, and evaluate a CAP to promote biospecimen collection for research purposes. Role: PI

CMS5331023 (Partridge) 07/01/12 – 06/30/15

Centers for Medicare & Medicaid Services
Health Care Innovation Challenge

The Deep South Cancer Navigation Network (DSCNN) will provide better health, better healthcare, and lower overall costs to cancer patients covered by Medicare or Medicaid in a high risk, high opportunity population located in a Deep South region of the nation by incorporating a large transformed healthcare workforce of hospital and community based lay patient navigators into the UAB Cancer Care Network (UABCCN) which includes the UAB Comprehensive Cancer Center (UABCCC) and 10 community based cancer centers located in 5 Deep South states. This UABCCN's goal is the delivery of the highest quality of care to cancer patients served by the network as close to home as possible. Role: PI

U54 CA118948 (Manne/Fouad) 09/23/05 – 08/31/16

NCI

Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership
The Partnership has goals of attaining excellence in research focused on the basis of cancer health disparities and on reducing the cancer burden. The primary objectives are to maintain progress in establishing productive cancer research programs at MSM and TU, to persist in developing a pipeline of prospective minority investigators at TU, and further expand cancer disparity research at the UAB Comprehensive Cancer Center. Role: Co-Investigator

P60MD000502 (Fouad) 09/30/07 – 03/31/17

NIMHD

Comprehensive Minority and Health Disparities Research Center (MHDRC) – Phase III
This application by the University of Alabama at Birmingham (UAB) proposes to expand our current NIMHD-funded P60 Center of Excellence – “Comprehensive Minority and Health Disparities Research Center (MHDRC)” to generate new knowledge on minority health and health disparities in the areas of cancer prevention and control, cardiovascular disease, and their risk factors in African American and Hispanic populations, with an emphasis on developing and testing interventions to reduce, and ultimately eliminate, these disparities. Role: Co-Investigator

U54MD008176 (Fouad) 09/26/12 – 09/30/17

NIH-NIMHD

Mid-South Transdisciplinary Collaborative Center for Health Disparities

The Mid-South Transdisciplinary Collaborative Center for Health Disparities Research (Mid-South TCC) seeks to reduce the disparities in chronic disease burden experienced by African Americans in six Mid-South states. Our goal is to address the social determinants that interplay to impact a person's health and produce disparate health outcomes of minority populations. We will focus on pathways to obesity and chronic illness and the mechanisms connecting these pathways to health disparities throughout the life-course. Role: Co-Investigator

NAATPN (Partridge) 09/01/14 – 08/31/15

CDC

Utilizing the NAATPN Network to Reduce Tobacco Related and Cancer Health Disparities
NAATPN's mission is to facilitate the development and implementation of comprehensive and community competent public health programs to benefit communities and people of African descent. Since its inception, NAATPN has facilitated and implemented numerous tobacco control activities that are based on the recommendations of CDC's Best Practices for Tobacco Control Programs and the Guide to Community Preventive Services. Role: PI